{
    "clinical_study": {
        "@rank": "159688", 
        "acronym": "ISAC", 
        "arm_group": [
            {
                "arm_group_label": "protons", 
                "arm_group_type": "Experimental", 
                "description": "16x4GyE protons"
            }, 
            {
                "arm_group_label": "Carbon ions", 
                "arm_group_type": "Experimental", 
                "description": "16x4GyE carbon ions"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and feasibility of primary\n      hypofractionated irradiation of sacrococcygeal chordoma with carbon ions or protons using\n      the raster scan technique."
        }, 
        "brief_title": "Ion Irradiation of Sacrococcygeal Chordoma", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Exposure to Artificially Accelerated Beams of Ionized Particles Generated by Synchrotrons", 
        "condition_browse": {
            "mesh_term": "Chordoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological confirmation of sacrococcygeal chordoma\n\n          -  Karnofsky performance status \u2265 70%\n\n          -  Patients age 18 - 80 years\n\n          -  Macroscopic tumour (MRI)\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Lack of macroscopic tumour\n\n          -  Tumor extension in craniocaudal direction >16cm\n\n          -  Metal implants at the level of the tumor which could influence the treatment planning\n\n          -  Inability of the patient to lie quiet for at least 20 minutes (eg due to pain)\n\n          -  Prior radiotherapy of the pelvic region\n\n          -  Simultaneous participation in another trial that could influence the results of the\n             study\n\n          -  Active medical implants without treatment approveal at the time of ion irradiation\n             (eg, cardiac pacemaker, defibrillator)"
            }, 
            "gender": "Both", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811394", 
            "org_study_id": "ISAC-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "protons", 
                "intervention_name": "protons", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Carbon ions", 
                "intervention_name": "carbon ions", 
                "intervention_type": "Radiation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "sacral chordoma", 
            "chordoma", 
            "carbon ion therapy", 
            "proton therapy", 
            "hypofractionation"
        ], 
        "lastchanged_date": "March 12, 2013", 
        "location": {
            "contact": {
                "email": "Matthias.uhl@med.uni-heidelberg.de", 
                "last_name": "Matthias Uhl, Dr.", 
                "phone": "+49 6221 568201"
            }, 
            "contact_backup": {
                "email": "Klaus.herfarth@med.uni-heidelberg.de", 
                "last_name": "Klaus Herfarth, Prof.Dr.", 
                "phone": "+49 6221 568201"
            }, 
            "facility": {
                "address": {
                    "city": "Heidelberg", 
                    "country": "Germany", 
                    "zip": "69125"
                }, 
                "name": "University of Heidelberg, Radiooncology, HIT"
            }, 
            "investigator": {
                "last_name": "Klaus Herfarth, Prof.Dr.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma", 
        "overall_contact": {
            "email": "Matthias.uhl@med.uni-heidelberg.de", 
            "last_name": "Matthias Uhl, Dr.", 
            "phone": "+49 6221 568201"
        }, 
        "overall_contact_backup": {
            "email": "Klaus.herfarth@med.uni-heidelberg.de", 
            "last_name": "Klaus Herfarth Herfath, Prof.Dr.", 
            "phone": "+49 6221 568201"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Office for Radiation Protection", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The evaluation is based on incidence of Grade 3-5 toxicity (NCI-CTC-AE) and/or discontinuation of the treatment for any reason. Endpoint is the proportion of treatments without Grade 3-5 toxicity (NCI-CTC-AE) up to 12 months after treatment and/or discontinuation of the treatment for any reason", 
            "measure": "safety and feasibility of hypofractionated irradiation in patients with sacrococygeal chordoma using ions (protons or carbon ions) in raster scan technique", 
            "time_frame": "From date of treatment start until 12 months after treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811394"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Heidelberg", 
            "investigator_full_name": "Klaus Herfarth - Dr. J. Debus", 
            "investigator_title": "Prof. Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "local progression free survival (LPFS) is determined from start of treatment until local progression in imaging (>10% size increase)", 
                "measure": "local progression free survival (LPFS)", 
                "time_frame": "From date of treatment start until the date of first documented progression  in MRI/CT scan assessed up to 12 months."
            }, 
            {
                "description": "Further objectives are overall survival (OS) from date of treatment start until the date of death from any cause assessed up to 12 months", 
                "measure": "Overall survival (OS)", 
                "time_frame": "From date of treatment start until the date of death from any cause assessed up to 12 months."
            }, 
            {
                "description": "Quality of life (QoL) evaluated with EORTC-QLQ30 questionnaire.", 
                "measure": "Quality of life (QoL)", 
                "time_frame": "From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment."
            }
        ], 
        "source": "Heidelberg University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Heidelberg University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}